Stock Track | Junshi Biosciences Soars on New Licensing Deal for Nasal Spray Project

Stock Track

2024-09-26

Shares of Junshi Biosciences (01877) surged 6.61% on Wednesday, September 26th, to close at a higher level amid positive news regarding a new licensing agreement for one of its pharmaceutical projects.

According to reports, a subsidiary of Junshi Biosciences, Shanghai Junshi Biosciences Co Ltd, entered into a license and cooperation agreement with Nanjing Jsiama Biopharmaceuticals for the development of a nasal spray product, dubbed IAMA-001.

While details of the agreement remain undisclosed, investors seem to have reacted positively to the news, anticipating potential future revenue streams and growth opportunities for the biopharmaceutical company. The licensing deal signals Junshi's commitment to expanding its product pipeline and exploring new therapeutic areas.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1107153024"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1107153024\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/1107153024?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-09-26 22:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1107153024","market":"us","top_or_hot":-1,"title":"Stock Track | Junshi Biosciences Soars on New Licensing Deal for Nasal Spray Project","media":"Stock Track","content":"<html><body><p>Shares of Junshi Biosciences (01877) surged 6.61% on Wednesday, September 26th, to close at a higher level amid positive news regarding a new licensing agreement for one of its pharmaceutical projects.</p>\n<p>According to reports, a subsidiary of Junshi Biosciences, Shanghai Junshi Biosciences Co Ltd, entered into a license and cooperation agreement with Nanjing Jsiama Biopharmaceuticals for the development of a nasal spray product, dubbed IAMA-001.</p>\n<p>While details of the agreement remain undisclosed, investors seem to have reacted positively to the news, anticipating potential future revenue streams and growth opportunities for the biopharmaceutical company. The licensing deal signals Junshi's commitment to expanding its product pipeline and exploring new therapeutic areas.</p></body></html>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta content=\"text/html; charset=utf-8\" http-equiv=\"Content-Type\"/>\n<meta content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\" name=\"viewport\"/>\n<meta content=\"telephone=no,email=no,address=no\" name=\"format-detection\"/>\n<title>Stock Track | Junshi Biosciences Soars on New Licensing Deal for Nasal Spray Project</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Junshi Biosciences Soars on New Licensing Deal for Nasal Spray Project\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2024-09-26 22:56</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Shares of Junshi Biosciences (01877) surged 6.61% on Wednesday, September 26th, to close at a higher level amid positive news regarding a new licensing agreement for one of its pharmaceutical projects.</p>\n<p>According to reports, a subsidiary of Junshi Biosciences, Shanghai Junshi Biosciences Co Ltd, entered into a license and cooperation agreement with Nanjing Jsiama Biopharmaceuticals for the development of a nasal spray product, dubbed IAMA-001.</p>\n<p>While details of the agreement remain undisclosed, investors seem to have reacted positively to the news, anticipating potential future revenue streams and growth opportunities for the biopharmaceutical company. The licensing deal signals Junshi's commitment to expanding its product pipeline and exploring new therapeutic areas.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01877","symbol_name":"君實生物","start_time":0,"source_url":"","article_id":"1107153024","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1107153024","pubTimestamp":1727362598,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Junshi Biosciences  surged 6.61% on Wednesday, September 26th, to close at a higher level amid positive news regarding a new licensing agreement for one of its pharmaceutical projects.According to reports, a subsidiary of Junshi Biosciences, Shanghai Junshi Biosciences Co Ltd, entered into a license and cooperation agreement with Nanjing Jsiama Biopharmaceuticals for the development of a nasal spray product, dubbed IAMA-001.While details of the agreement remain undisclosed, investors s","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01877":"君实生物"},"translate_title":"股票赛道君实生物因鼻喷雾剂项目新许可协议而飙升","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01877":1},"content_text":"Shares of Junshi Biosciences (01877) surged 6.61% on Wednesday, September 26th, to close at a higher level amid positive news regarding a new licensing agreement for one of its pharmaceutical projects.\nAccording to reports, a subsidiary of Junshi Biosciences, Shanghai Junshi Biosciences Co Ltd, entered into a license and cooperation agreement with Nanjing Jsiama Biopharmaceuticals for the development of a nasal spray product, dubbed IAMA-001.\nWhile details of the agreement remain undisclosed, investors seem to have reacted positively to the news, anticipating potential future revenue streams and growth opportunities for the biopharmaceutical company. The licensing deal signals Junshi's commitment to expanding its product pipeline and exploring new therapeutic areas.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1}}}